JPRN-jRCT2080221827未知1 期
A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Japanese men or women at least 20 years of age
- •- Histologically confirmed CLL (excluding small lymphocytic lymphoma (SLL)), DLBCL, FL, or MM.
- •- Karnofsky Performance Status: 70 or more
- •- Life expectancy of 12 weeks or more
排除标准
- •- Any available standard line of therapy known to be life-prolonging or life-saving
- •- Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancer
- •- Previous therapy directed against CD19, such as monoclonal antibodies or Mab conjugates
研究者
相似试验
已完成
1 期
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell MalignanciesB-cell MalignanciesCancerNCT00983619MedImmune LLC136
已完成
1 期
A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell MalignanciesBlood CancerAdvanced B Cell MalignanciesNCT01957579AstraZeneca32
进行中（未招募）
1 期
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CRelapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CTIS2023-504403-92-00Janssen - Cilag International200
进行中（未招募）
1 期
An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell MalignanciesRelasped or refractory advanced B-cell malignancies:chronic lymphocytic leukemia (CLL), multiple myeloma (MM), B-cell non-Hodgkin’s lymphoma (NHL) (subtypes: follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL))MedDRA version: 12.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaMedDRA version: 12.1Level: LLTClassification code 10012818Term: Diffuse large B-cell lymphomaMedDRA version: 12.1Level: LLTClassification code 10028228Term: Multiple myelomaMedDRA version: 12.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaEUCTR2009-016378-34-FRMedImmune, LLC136
进行中（未招募）
1 期
A Study of MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell MalignanciesRelapsed or refractory advanced B-cell malignancies: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin’s lymphoma (NHL) (subtypes: follicular lymphoma (FL), diffuse large B-cell lymphoma(DLBCL), mantle cell lymphoma, and anti-CD20-refractory aggressive lymphomas)MedDRA version: 20.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10067070 Term: Follicular B-cell non-Hodgkin's lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10012818 Term: Diffuse large B-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016378-34-BEMedImmune LLC193